Bengaluru-based Anthem Biosciences Limited, a prominent player in the Contract Research and Manufacturing Services (CRAMS) space, is set to launch its Initial Public Offering (IPO) on Monday, July 14, 2025. The price band for the Anthem Biosciences IPO has been fixed at ₹540 to ₹570 per equity share, each having a face value of ₹2.
The Anchor Investor bidding will take place on Friday, July 11, 2025, ahead of the three-day public issue that closes on Wednesday, July 16, 2025. The Anthem Biosciences IPO is purely an Offer for Sale (OFS), aggregating up to ₹33,950 million, allowing existing shareholders to partially divest their holdings.
Also Read: Wadhwani Hub at IIT Bombay to Accelerate AI-Driven Innovation in Biosciences
Anthem Biosciences IPO: Offer Details
Investors can bid for a minimum of 26 equity shares and in multiples of 26 thereafter. The Anthem Biosciences IPO offer includes:
- ₹3,500 million worth of equity shares each by promoters Ganesh Sambasivam and K. Ravindra Chandrappa
- ₹13,250 million by Viridity Tone LLP
- ₹3,200 million each by Portsmouth Technologies LLC, Malay J Barua, Rupesh N Kinekar, and Satish Sharma
- ₹800 million by Prakash Kariabettan
- ₹100 million by K. Ramakrishnan
A total of ₹82.50 million worth of shares is reserved for eligible employees, with a ₹50 per share discount under the Employee Reservation Portion.
Market Allocation Structure
The Anthem Biosciences IPO is being launched via the Book Building Process and complies with Rule 19(2)(b) of the Securities Contracts (Regulation) Rules and the SEBI ICDR Regulations. The breakdown is as follows:
- Qualified Institutional Buyers (QIBs): Up to 50% of the offer is reserved, with up to 60% of the QIB portion allocated to Anchor Investors on a discretionary basis. One-third of this Anchor allocation is earmarked for domestic mutual funds.
- Non-Institutional Investors (NIIs): 15% of the offer, divided into two sub-categories for bids of ₹0.2–1 million and above ₹1 million. Oversubscription in one can be reallocated to the other.
- Retail Individual Investors (RIIs): 35% of the offer is reserved, subject to valid bids at or above the offer price.
- Employees: Eligible employees participating in the Employee Reservation Portion will be allotted shares on a proportionate basis.
Listing and Application Process
Shares will be listed on both NSE and BSE, offering retail and institutional investors alike the opportunity to invest in one of India’s leading CRAMS companies.
All bidders, excluding Anchor Investors, must participate using the Application Supported by Blocked Amount (ASBA) mechanism. Retail investors can also use the UPI system. Anchor Investors will participate via separate institutional allotment processes and are not permitted to apply through ASBA.
Also Read: Venture Center Leap Global Accelerator Launches First Cohort Featuring 15 Deeptech Startups
Lead Managers and Prospectus
The IPO is being managed by a consortium of Book Running Lead Managers (BRLMs), including:
- JM Financial Limited
- Citigroup Global Markets India Pvt. Ltd.
- J.P. Morgan India Pvt. Ltd.
- Nomura Financial Advisory and Securities (India) Pvt. Ltd.
The Red Herring Prospectus (RHP) dated July 8, 2025, is available for public review and can be accessed here.
Founded in 2007, Anthem Biosciences is a leading provider of Contract Research and Manufacturing Services (CRAMS) to global pharmaceutical and biotech companies. The company specializes in drug discovery, development, and manufacturing services across various therapeutic segments.
The Anthem Biosciences IPO is expected to enhance liquidity for shareholders and broaden Anthem’s visibility among institutional and retail investors.
